<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620788</url>
  </required_header>
  <id_info>
    <org_study_id>LIEMS1111</org_study_id>
    <nct_id>NCT01620788</nct_id>
  </id_info>
  <brief_title>Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment</brief_title>
  <official_title>Randomized, Phase 3, Multicenter, Open Label, Evaluating the Effect of the Treatment of Indapamide 1.5mg/Losartan 50mg and Indapamide 1.5mg/Losartan 100mg, Compared With Hyzaar® in the Treatment of Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy of indapamide 1.5mg / losartan
      50mg and indapamide 1.5mg / losartan 100mg on reduction of blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  open label,randomized, multicenter

        -  Experiment duration: 12 weeks.

        -  05 visits (day 0 - randomization), (day 1 - 2 weeks pos-randomization), (day 2 - 4 weeks
           pos-randomization), (day 3 - 8 weeks pos-randomization) and (day 4 - 12 weeks
           pos-randomization).

        -  evaluate the efficacy of a medication associated with two antihypertensive agents in two
           fixed doses compared to the Hyzaar® in patients with hypertension

        -  Adverse events evaluation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in systemic blood pressure measurements after 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Will be Evaluated by the Adverse Events Occurrences</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">636</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Indapamide 1.5mg / Losartan 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Indapamide 1.5mg / Losartan 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyzaar® (Losartan 50mg/Hydrochlorothiazide12,5mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyzaar® (Losartan 100mg/Hydrochlorothiazide 25mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indapamide / Losartan</intervention_name>
    <description>1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day</description>
    <arm_group_label>Indapamide 1.5mg / Losartan 50mg</arm_group_label>
    <other_name>Indapamide 1.5mg / Losartan 50mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indapamide / Losartan</intervention_name>
    <description>1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day</description>
    <arm_group_label>Indapamide 1.5mg / Losartan 100mg</arm_group_label>
    <other_name>Indapamide 1.5mg / Losartan 100mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyzaar®</intervention_name>
    <description>1 tablet of Hyzaar®, oral, a day</description>
    <arm_group_label>Hyzaar® (Losartan 50mg/Hydrochlorothiazide12,5mg)</arm_group_label>
    <other_name>Losartan 50mg/Hydrochlorothiazide12,5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyzaar®</intervention_name>
    <description>1 tablet of Hyzaar®, oral, a day</description>
    <arm_group_label>Hyzaar® (Losartan 100mg/Hydrochlorothiazide 25mg)</arm_group_label>
    <other_name>Losartan 100mg/Hydrochlorothiazide 25mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults male or female aged ≥ 18 years old;

          -  Patients with a diagnosis of Hypertension (defined by the medical investigator)
             treated with monotherapy or at least two blood pressure measurements ≥ 140/90, in a
             sitting position with a 5' interval between measurements,

          -  Patients with normal lab tests results in the last six months or that the investigator
             consider not clinically significant,

          -  Patient who accept the discontinuation of previous hypertension therapy.

        Exclusion Criteria:

          -  Patients with blood pressure ≥ 180/100 mmHg;

          -  Patients with uncontrolled hypertension (≥ 140/90 mmHg) treated with thiazide
             diuretics;

          -  Presence of concomitant coronary artery disease, congestive heart failure, diabetes
             and renal failure (creatinine&gt; 1.5 mg / dL);

          -  Patients with hypo or hyperkalemia (serum potassium outside normal range);

          -  Patients with ALT greater than 2.5 the upper limit of normal or active liver disease;

          -  Pregnant women, or women in childbearing age who are not in use effective
             contraception or intending to become pregnant during the study period;

          -  Patients on drug or alcohol abuse in the last two years;

          -  Patients with secondary hypertension (renovascular disease, pheochromocytoma,
             Cushing's syndrome);

          -  Patients with allergic reactions or hypersensitivity to ACE inhibitors, diuretics or
             medications containing sulfa and / or any excipients of formulation;

          -  Refusal or inability to provide the Informed Consent Term.;

          -  Refusal to discontinue the anti-hypertensive medication.

          -  Patients at the discretion of the investigator does not have indication for
             discontinuing the current medications;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roberto B. Amazonas, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Allergisa</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro A Crippa, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 29, 2012</study_first_submitted>
  <study_first_submitted_qc>June 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Indapamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

